Stocks in play: Knight Therapeutics Inc.
Has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Market Regulation Chamber (“CMED”). As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024. Knight Therapeutics Inc. shares T.GUD are trading down $0.02 at $4.55.
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.